Salvia BioElectronics, a clinical-stage medical device company based in Eindhoven, the Netherlands, has successfully completed a $60 million Series B financing round to advance its pioneering neuromodulation therapy for chronic migraine. The oversubscribed round was led by Innovation Industries, with participation from Invest-NL, EIC Fund, and existing investors including Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, Brabant Development Agency (BOM), and Thuja Capital.
The funding will enable Salvia to complete clinical development and prepare for commercial launch of MySalvia Therapy, which is currently being evaluated in the RECLAIM study, a multi-center, double-blind, sham-controlled clinical trial for people with chronic migraine. The proceeds will also support the company's efforts to obtain FDA market authorization in the United States and regulatory approvals in Europe and Australia.
Addressing Critical Unmet Medical Need
Migraine represents one of the leading causes of disability worldwide, resulting in an estimated $110 billion annually in lost productivity and medical costs in the EU and US alone. Current treatment options often fail to provide sufficient relief, with the majority of chronic patients discontinuing their medication within the first year. This high dropout rate underscores the urgent need for alternative therapeutic approaches.
"Chronic migraine is not 'just a headache'. It is a debilitating neurological condition that forces people out of their social life, their work, and the life they want to live," said Hubert Martens, founder and CEO of Salvia BioElectronics. "Our mission is to restore their freedom. MySalvia Therapy is designed to provide not just relief, but meaningful and lasting impact."
Breakthrough Device Technology
Salvia's FDA-designated Breakthrough Device represents a novel approach to migraine treatment through proprietary neuromodulation technology. The therapy utilizes two ultra-thin implants placed just beneath the skin of the forehead and the back of the head, targeting key nerves involved in migraine pathophysiology.
The system is designed to be significantly less invasive than conventional neuromodulation technologies, reducing surgical complexity and patient recovery time while offering a visually discreet solution. MySalvia Therapy puts patients in full control through a user-activated, on-demand approach. Patients use an external wearable device and simply press a button to deliver targeted stimulation exactly when and where it is needed.
Early clinical data indicates a potential reduction in the frequency and intensity of migraine attacks when using the company's neuromodulation technology. The RECLAIM study is currently underway in Europe and Australia, with additional studies planned in the US to evaluate the therapy's safety and effectiveness.
Investor Confidence in Neuromodulation Innovation
"Salvia BioElectronics is redefining the migraine therapy landscape with a bold, patient-centered approach that combines cutting-edge neuromodulation with an elegant, minimally invasive design," said Caaj Greebe, Partner at Innovation Industries. "At Innovation Industries, we invest in breakthrough technologies that have the potential to solve the most pressing real-world challenges and Salvia BioElectronics does exactly that: offering life-changing solutions for millions of people living with chronic migraine."
Innovation Industries is a leading European deep tech venture capital firm with €1 billion in capital under management, focusing on visionary science and engineering-based companies that tackle global challenges.
Expanding Treatment Horizons
Beyond chronic migraine, Salvia's technology holds promise for treating cluster headache, a severely painful neurological condition with few effective treatment options currently available. The company, founded in 2017, is led by a team of industry veterans with extensive experience in medical devices and neuromodulation.
With this Series B funding, Salvia is positioned to advance toward regulatory approval and commercialization, with the ultimate goal of reaching millions of people affected by chronic migraine worldwide. The company's approach represents a significant step forward in addressing the substantial unmet medical need in migraine treatment, potentially offering new hope for patients who have not responded to existing therapies.
